SEC Form 4 · accession 0001178913-26-003859
Evogene Ltd. · EVGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leon Recanati
Director
Period of report
Aug 4, 2026
Accepted (ET)
Aug 5, 2026 · 4:07 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001574565
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 4, 2026 | P | 800,000 | $0.50 | A | 883,886 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $72.46 | holding | — | — | — | Jun 11, 2020 | May 18, 2026 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)F2 | $54.32 | holding | — | — | — | Jun 11, 2021 | May 16, 2027 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)F2 | $32.05 | holding | — | — | — | Jun 11, 2022 | Jun 25, 2028 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)F2 | $17.68 | holding | — | — | — | Jun 11, 2023 | Jul 30, 2029 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)F2 | $12.03 | holding | — | — | — | Jun 11, 2024 | Nov 17, 2030 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)F2 | $39.32 | holding | — | — | — | Jun 11, 2025 | Jun 11, 2031 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)F2 | $28.62 | holding | — | — | — | Aug 10, 2022 | Sep 1, 2031 | Ordinary Shares | 1,800 | 1,800 | D |
| Stock Option (right to buy)F2 | $10.50 | holding | — | — | — | Sep 15, 2023 | Sep 15, 2032 | Ordinary Shares | 1,800 | 1,800 | D |
| Stock Option (right to buy)F2 | $6.03 | holding | — | — | — | May 11, 2024 | May 11, 2033 | Ordinary Shares | 1,800 | 1,800 | D |
| Stock Option (right to buy)F2 | $7.16 | holding | — | — | — | Jun 13, 2025 | Jun 13, 2034 | Ordinary Shares | 1,800 | 1,800 | D |
| Stock Option (right to buy)F2,F3 | $1.29 | holding | — | — | — | — | Aug 18, 2035 | Ordinary Shares | 2,500 | 2,500 | D |
Explanation of responses
- F1The price reported in column 4 of this row is a weighted average price. These shares were purchased in multiple transactions on August 4, 2026 within a range of prices per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
- F2There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F3The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.
Remarks
Exhibit 24.1 - Power of Attorney.